Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Gemina Laboratories Ltd
(CSE:
GLAB
)
0.4500
+0.0500 (+12.50%)
Streaming Delayed Price
Updated: 10:39 AM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Gemina Laboratories Ltd
< Previous
1
2
Next >
Gemina Laboratories Strategic Update
July 10, 2024
Via
ACCESSWIRE
Life Science Virtual Investor Forum Presentations Now Available for Online Viewing
June 21, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Gemina Laboratories Commences Trading on the OTCQB Market in the United States
June 20, 2024
Via
ACCESSWIRE
Life Sciences Virtual Investor Forum Agenda Announced for June 20th
June 18, 2024
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Gemina Labs Announces Addition to its IP Portfolio
April 09, 2024
Via
ACCESSWIRE
Gemina Laboratories to Participate in Poster Session at American Association of Clinical Chemistry Annual Scientific Meeting
June 15, 2023
Via
ACCESSWIRE
Gemina Labs to Present at the Life Science Investor Forum June 20th
June 17, 2024
Company invites individual and institutional investors, as well as advisors and analysts, to attend in person or online at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Gemina Laboratories Sign First Strategic License Agreement
April 02, 2024
Via
ACCESSWIRE
Gemina Labs Strategic Update: Focusing on Respiratory Infections and Strategic Partnerships
March 21, 2024
Via
ACCESSWIRE
Gemina Announces Closing of $910,000 Convertible Note Financing
March 19, 2024
Via
ACCESSWIRE
Gemina's Recent Investment into RAPIvD Sees Immediate Progress
December 13, 2022
Via
ACCESSWIRE
ReadyGo Diagnostics Initiates An Assay Development Contract With Gemina Laboratories For The Detection Of Dengue From Saliva Samples
October 10, 2023
Via
Get News
Gemina Laboratories Announces Major Breakthrough in Environmentally Friendly Lateral Flow Test Design by Removing the Requirement for Nitrocellulose
July 25, 2023
Via
ACCESSWIRE
Gemina Laboratories and ReadyGo Diagnostics Achieve Mycobacterium Tuberculosis Diagnosis in Saliva
June 05, 2023
Via
ACCESSWIRE
Gemina Labs Antibody Immobilization Chemistry Platform Demonstrates Major Lateral Flow Assay Performance Improvement
May 17, 2023
Via
ACCESSWIRE
Gemina Laboratories to Host Investor Webinar on March 30, 2023
March 27, 2023
Via
ACCESSWIRE
Gemina Labs Appoints Diagnostic Strategist Martha Najib to the Board
March 07, 2023
Via
ACCESSWIRE
Gemina Labs Announces Appointment of Healthcare Industry Leader Dr. Bola Grace to The Board of Directors
January 25, 2023
Via
ACCESSWIRE
Gemina Labs Appoints Top Ranked UK Analyst and Scientist, Dr. Stefan Hamill as Vice President, Strategy
January 23, 2023
Via
ACCESSWIRE
Gemina Labs Strategic Update: Respiratory Infections the Immediate Focus and New Strategic Partnerships on the Horizon
January 10, 2023
Via
ACCESSWIRE
Gemina Labs Completes Influenza A/B Diagnostic Test Prototype
January 06, 2023
Via
ACCESSWIRE
Gemina Labs Appoints Dr Michael Shannon as Chair of Clinical Advisory Board
December 20, 2022
Via
ACCESSWIRE
Gemina Labs Announces Research Collaboration on Next Generation Biosensors
December 19, 2022
Via
ACCESSWIRE
Gemina Labs Announces Strategic Stake in British Rapid Test Optimizer Rapivd Limited
December 07, 2022
Via
ACCESSWIRE
Gemina Labs Enters into Licence and Manufacturing Agreements
October 06, 2022
Via
ACCESSWIRE
Gemina Labs Presents at the H.C. Wainwright Global Investment Conference
September 12, 2022
Via
ACCESSWIRE
Gemina Labs Appoints Diagnostic Executive Brian Firth as Chief Executive Officer
September 06, 2022
Via
ACCESSWIRE
Gemina Labs Announces Closing Of Concurrent Private Placement
July 11, 2022
VANCOUVER, BC / ACCESSWIRE / July 11, 2022 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the "Company" or "Gemina") is pleased to announce the closing of its previously announced non-brokered private...
From
Gemina Laboratories Ltd.
Via
AccessWire
Gemina Announces Closing Of Prospectus Supplement Offering And Update To Concurrent Non-brokered Private Placement
June 30, 2022
VANCOUVER, BC / ACCESSWIRE / June 30, 2022 / Gemina Laboratories Ltd. (the "Company" or "Gemina") (CSE:GLAB)(FRA:8I7) is pleased to announce that the Company has closed its previously announced...
From
Gemina Laboratories Ltd.
Via
AccessWire
Gemina Announces Filing of Prospectus Supplement
June 24, 2022
VANCOUVER, BC / ACCESSWIRE / June 24, 2022 / Gemina Laboratories Ltd. (the "Company" or "Gemina") (CSE:GLAB)(FRA:8I7) is pleased to announce that the Company has entered into an agency agreement dated...
From
Gemina Laboratories Ltd.
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.